Scandion Oncology Q2 2021: Progress in the making - Redeye

Redeye comments on Scandion’s Q2‘21 report, following an eventful quarter. Towards the end of Q2, Scandion presented promising CORIST phase II dose-finding data. We are encouraged by the company’s progress and reiterate our Base Case at SEK 24 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/819016/scandion-oncology-q2-2021-progress-in-the-making?utm_source=finwire&utm_medium=RSS